High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
| Autor: | Hao Chen, Xiaofang Guo, Tongyu Lin, Xiaofei Sun, Zijun Zhen, Wenqi Jiang, Zhongjun Xia, Huiqiang Huang, Juan Wang, Jietian Jin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Oncology
Original article Cancer Research medicine.medical_specialty Poor prognosis Programmed cell death business.industry High serum Ligand (biochemistry) lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens lcsh:RC254-282 Blockade 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine mental disorders medicine Hodgkin lymphoma Peripheral blood monocyte business 030215 immunology Programmed death |
| Zdroj: | Translational Oncology, Vol 11, Iss 3, Pp 779-785 (2018) Translational Oncology |
| ISSN: | 1936-5233 |
| Popis: | Blockade of the programmed cell death 1-programmed cell death ligand 1 pathway is a new and promising therapeutic approach in Hodgkin lymphoma (HL). To our knowledge, the impact of soluble programmed cell death ligand 1 (sPD-L1) serum levels on HL patient prognosis has not yet been investigated. In this study, the prognostic value of sPD-L1 was assessed in patients with HL. We measured serum sPD-L1 levels and identified their prognostic value in 108 newly diagnosed HL patients using an enzyme-linked immunosorbent assay (ELISA). We found higher serum sPD-L1 concentrations in HL patients than in healthy controls. The best sPD-L1 cutoff value for predicting disease progression risk was 25.1674 ng/ml. The 4-year progression-free survival (PFS) rates for the high-sPD-L1 and low-sPD-L1 groups were 78.8% and 93.3%, respectively. Multivariate survival analysis showed that advanced stage and higher sPD-L1 levels (>25.1674 ng/ml) were independent prognostic factors for shorter PFS. In addition, higher sPD-L1 levels were positively correlated with advanced stage and negatively correlated with peripheral blood monocyte number. The serum sPD-L1 level is an independent prognostic factor for PFS in HL patients and may allow identification of a subgroup of patients who require more intensive therapy and who may benefit from anti-PD-1 agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|